Martingale Asset Management L P Reduces Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Martingale Asset Management L P cut its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 28.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,985 shares of the specialty pharmaceutical company’s stock after selling 1,584 shares during the period. Martingale Asset Management L P’s holdings in Jazz Pharmaceuticals were worth $491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $25,000. Quadrant Capital Group LLC increased its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 101 shares during the last quarter. CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at $28,000. Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at $29,000. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

JAZZ has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Barclays reissued an “overweight” rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Morgan Stanley restated an “overweight” rating and set a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Needham & Company LLC reiterated a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday. Finally, HC Wainwright boosted their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research note on Monday, March 10th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $187.71.

Insider Activity

In related news, EVP Neena M. Patil sold 3,800 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,736 shares of company stock worth $4,023,305. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 1.5 %

Shares of Jazz Pharmaceuticals stock opened at $100.50 on Monday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $6.10 billion, a price-to-earnings ratio of 14.15, a PEG ratio of 1.04 and a beta of 0.42. The firm’s 50-day moving average is $129.67 and its two-hundred day moving average is $122.77. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.